Kamada (NASDAQ:KMDA) Hits New 52-Week High – Here’s Why

Kamada Ltd. (NASDAQ:KMDA)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $8.90 and last traded at $8.8760, with a volume of 36583 shares trading hands. The stock had previously closed at $8.50.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on KMDA shares. HC Wainwright lifted their target price on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.00.

Kamada Stock Performance

The stock has a market cap of $498.04 million, a PE ratio of 24.06, a price-to-earnings-growth ratio of 0.75 and a beta of 0.94. The company has a 50 day moving average of $7.86 and a two-hundred day moving average of $7.26.

Institutional Trading of Kamada

Institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC acquired a new stake in Kamada in the 2nd quarter worth about $1,972,000. Jane Street Group LLC acquired a new stake in shares of Kamada in the first quarter worth approximately $582,000. Goldman Sachs Group Inc. purchased a new stake in shares of Kamada during the first quarter worth approximately $497,000. Essex Investment Management Co. LLC increased its position in shares of Kamada by 22.4% during the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock worth $2,751,000 after purchasing an additional 72,602 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Kamada in the 2nd quarter valued at $472,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.